Search results
1 company and 11 research reports found for "GlaxoSmithKline"
Company results
- GlaxoSmithKline
GlaxoSmithKline is a leading multinational pharmaceutical company with diversified operations. Its k...
Sector reports
No sector reports have been found.
Research results
Ligand Pharmaceuticals
ENABLE-ing growth
QuickView | Pharmaceutical & Healthcare | 14/11/2011Ligand Pharmaceuticals’ partner GlaxoSmithKline presented Phase III data from two trials that showed that Promacta raised and maintained platele...
Vectura
Double deal for VR315
Update | Pharmaceutical & Healthcare | 11/08/2011Vectura has licensed the US and RoW (ex-EU) rights to VR315, its generic fixed dose combination – believed to be a generic version of GlaxoSmith...
SkyePharma
Beyond Pulmicort
Review | Pharmaceutical & Healthcare | 30/03/2011SkyePharma finished 2010 with £29m in gross cash, posting group revenue of £58m and a normalised pre-tax profit of £8.3m. Its investment case remai...
Proximagen Group
GSK assets acquired
Update | Pharmaceutical & Healthcare | 22/12/2010Proximagen has announced an exclusive deal with GlaxoSmithKline to acquire global rights to two drug development programmes for CNS indications. Both ...
GlaxoSmithKline
Beyond the cliff
QuickView | Pharmaceutical & Healthcare | 05/02/2010GlaxoSmithKline’s transformation under CEO Andrew Witty continues, with clear evidence of the changes, especially in emerging markets. In additio...
Vectura
$6m Sandoz milestone
Update | Pharmaceutical & Healthcare | 14/08/2009Vectura has received a $6m milestone payment from Sandoz (Novartis) relating to the development of VR315, a key project widely believed to be a generi...
Vernalis
GlaxoSmithKline deal
Update | Pharmaceutical & Healthcare | 07/08/2009Vernalis has signed a licensing agreement with GlaxoSmithKline (GSK) relating to an undisclosed internally generated research target that will initial...
BTG
Licensee deal with GSK
Flash note | Pharmaceutical & Healthcare | 25/10/2007BTG confirmed yesterday that it is to receive a $10m initial payment and a 50% share of downstream milestones totalling up to $525m (i.e. $262.5m), as...
Futura Medical
Big pharma blow
Update | Pharmaceutical & Healthcare | 14/05/2007In a scenario that has come to typify the pitfalls of biotech companies’ relationships with big pharma, GlaxoSmithKline has pulled out of its de...
Futura Medical
GSK option on pain
Update | Pharmaceutical & Healthcare | 20/04/2007GlaxoSmithKline has acquired exclusive negotiating rights to pain relief product using Futura’s DermaSys technology, including presumably the di...
Futura Medical
Transforming events
Quarterly Update - Announcement | Pharmaceutical & Healthcare | 05/07/2006Futura Medical yesterday announced the long-awaited commercial partnership for its MED2002 non-prescription topical treatment for erectile dysfunction...
